Ock, Chan-Young <br/><br/>
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.  [electronic resource] 

 -  The Korean journal of internal medicine  Sep 2019 
 - 1116-1124 p.  digital 
<br/><br/> Publication Type: Journal Article; Validation Study 
<br/><br/><label>ISSN: </label>2005-6648 
<br/><br/><label>Standard No.: </label>10.3904/kjim.2018.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anaplastic Lymphoma Kinase--antagonists & inhibitors<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Clinical Decision-Making<br/>Crizotinib--adverse effects<br/>Decision Support Techniques<br/>Disease Progression<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Progression-Free Survival<br/>Protein Kinase Inhibitors--adverse effects<br/>Reproducibility of Results<br/>Risk Assessment<br/>Risk Factors<br/>Time Factors<br/>Young Adult